# Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination

> **NCT01983540** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 558 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Whooping Cough
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine
- **BIOLOGICAL:** DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine
- **BIOLOGICAL:** Infanrix hexa + Prevenar + Rotarix vaccine

## Key facts

- **NCT ID:** NCT01983540
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 558 (ACTUAL)
- **Last updated:** 2016-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01983540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01983540, "Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01983540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*